BC Innovations | Nov 15, 2018
Product R&D

Tempest takes PPAR alpha into cancer

Tempest Therapeutics Inc.’s first data from its preclinical PPARα program gave it the support it was looking for to repurpose the cardiovascular target for cancer. Tapping into the emerging field of cancer immuno-metabolism, Tempest is...
BC Innovations | Dec 17, 2015
Distillery Therapeutics

Therapeutics: Pyruvate dehydrogenase kinase 2 (PDK2); PDK4

Neurology INDICATION: Pain Mouse studies suggest dual PDK2 / PDK4 inhibitors could help treat inflammatory pain. In mice, intraplantar administration of an inflammatory adjuvant increased hindpaw expression of PDK2 and PDK4 compared with vehicle. In...
Items per page:
1 - 2 of 2